Finepoint Capital LP increased its stake in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 51.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 657,071 shares of the biotechnology company's stock after purchasing an additional 223,600 shares during the quarter. Prothena makes up about 0.6% of Finepoint Capital LP's portfolio, making the stock its 15th largest holding. Finepoint Capital LP owned about 1.22% of Prothena worth $9,100,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also added to or reduced their stakes in PRTA. Wellington Management Group LLP increased its holdings in shares of Prothena by 22.8% during the fourth quarter. Wellington Management Group LLP now owns 5,130,876 shares of the biotechnology company's stock worth $71,063,000 after buying an additional 952,088 shares in the last quarter. Vanguard Group Inc. raised its position in Prothena by 11.5% in the fourth quarter. Vanguard Group Inc. now owns 1,403,838 shares of the biotechnology company's stock valued at $19,443,000 after purchasing an additional 144,737 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Prothena by 1,122.9% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company's stock valued at $8,812,000 after purchasing an additional 483,673 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Prothena by 93.7% during the fourth quarter. JPMorgan Chase & Co. now owns 387,350 shares of the biotechnology company's stock worth $5,365,000 after purchasing an additional 187,364 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Prothena by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 327,151 shares of the biotechnology company's stock valued at $4,531,000 after buying an additional 2,189 shares during the period. Institutional investors own 97.08% of the company's stock.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on PRTA shares. Royal Bank of Canada reduced their target price on shares of Prothena from $24.00 to $20.00 and set a "sector perform" rating on the stock in a report on Friday, February 21st. Chardan Capital reissued a "buy" rating and issued a $40.00 price objective on shares of Prothena in a research note on Friday, February 21st. Oppenheimer raised their target price on Prothena from $58.00 to $62.00 and gave the stock an "outperform" rating in a research report on Friday, February 7th. Piper Sandler upped their price target on Prothena from $94.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Prothena in a research report on Friday, February 21st. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $55.00.
View Our Latest Analysis on Prothena
Prothena Trading Up 4.0 %
NASDAQ PRTA traded up $0.39 during trading hours on Friday, hitting $10.08. 124,376 shares of the company's stock were exchanged, compared to its average volume of 442,912. The firm has a market cap of $542.58 million, a price-to-earnings ratio of -4.38 and a beta of 0.07. The stock has a 50-day simple moving average of $13.45 and a 200 day simple moving average of $14.80. Prothena Co. plc has a 1-year low of $9.30 and a 1-year high of $25.42.
Prothena (NASDAQ:PRTA - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.06). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The company had revenue of $2.12 million for the quarter, compared to analyst estimates of $7.53 million. On average, sell-side analysts anticipate that Prothena Co. plc will post -4.04 earnings per share for the current fiscal year.
About Prothena
(
Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Further Reading
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
